Clinical trial
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab…
NCT00100737 · Chiron Corporation, Industry · Terminated
Key facts
| NCT number | NCT00100737 |
|---|---|
| Title | Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL) |
| Official title | A Phase 2 Randomized, Open-Label, Controlled Trial of the Addition of 8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab in the Treatment of Rituximab Naïve Subjects With Follicular Non-Hodgkin's Lymphoma, Refractory or Relapsed After… |
| Lead sponsor | Chiron Corporation, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | interleukin-2, rituximab |
| Enrollment | 300 |
| First posted | Jan 7, 2005 |
| Last update posted | Feb 6, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: